These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 33387488)

  • 1. APX005M, a CD40 monoclonal antibody, for patients with pancreatic adenocarcinoma.
    Reni M
    Lancet Oncol; 2021 Jan; 22(1):10-11. PubMed ID: 33387488
    [No Abstract]   [Full Text] [Related]  

  • 2. Harnessing immune responses in the tumor microenvironment: all signals needed.
    Le DT; Jaffee EM
    Clin Cancer Res; 2013 Nov; 19(22):6061-3. PubMed ID: 24097857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging antibodies for the treatment of pancreatic cancer.
    Andrikou K; Peterle C; Pipitone S; Salati M; Cascinu S
    Expert Opin Emerg Drugs; 2017 Mar; 22(1):39-51. PubMed ID: 28253833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Optimal duration and timing of adjuvant chemotherapy after resection for pancreatic ductal adenocarcinoma].
    Strobel O; Büchler MW
    Chirurg; 2014 Jun; 85(6):543. PubMed ID: 24824005
    [No Abstract]   [Full Text] [Related]  

  • 5. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
    Sclafani F; Iyer R; Cunningham D; Starling N
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancreatic ductal adenocarcinoma: metastatic disease.
    Muñoz Martín AJ; Adeva J; Martínez-Galán J; Reina JJ; Hidalgo M
    Clin Transl Oncol; 2017 Dec; 19(12):1423-1429. PubMed ID: 28623515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing versus duration of adjuvant therapy for pancreatic cancer: all the lessons we need in life are taught to us as children.
    Chan E; Berlin J
    J Clin Oncol; 2014 Feb; 32(6):487-8. PubMed ID: 24419124
    [No Abstract]   [Full Text] [Related]  

  • 8. Homeostatic restoration of desmoplastic stroma rather than its ablation slows pancreatic cancer progression.
    Froeling FE; Kocher HM
    Gastroenterology; 2015 Apr; 148(4):849-50. PubMed ID: 25724458
    [No Abstract]   [Full Text] [Related]  

  • 9. Pancreatic cancer: New insights into PDAC growth promotion via a BAG3-mediated paracrine loop.
    Ray K
    Nat Rev Gastroenterol Hepatol; 2015 Dec; 12(12):669. PubMed ID: 26577348
    [No Abstract]   [Full Text] [Related]  

  • 10. A newly developed anti-Mucin 13 monoclonal antibody targets pancreatic ductal adenocarcinoma cells.
    Nishii Y; Yamaguchi M; Kimura Y; Hasegawa T; Aburatani H; Uchida H; Hirata K; Sakuma Y
    Int J Oncol; 2015 Apr; 46(4):1781-7. PubMed ID: 25672256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.
    Pokorny AMJ; Chin VT; Nagrial AM; Yip D; Chantrill LA
    Intern Med J; 2018 Jun; 48(6):637-644. PubMed ID: 29898269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CD40-CD154 interaction would correlate with proliferation and immune escape in pancreatic ductal adenocarcinoma.
    Shoji Y; Miyamoto M; Ishikawa K; Yoshioka T; Mishra R; Ichinokawa K; Matsumura Y; Itoh T; Shinohara T; Hirano S; Kondo S
    J Surg Oncol; 2011 Mar; 103(3):230-8. PubMed ID: 21337550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Preliminary results of cytotoxic monoclonal antibody treatment in pancreatic adenocarcinomas and biliary tract carcinomas].
    Leborgne J; Douillard JY; Kremer M
    Ann Chir; 1990; 44(5):338-41. PubMed ID: 2372194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe Pneumonitis after Nivolumab Treatment Accompanied by Acute Pulmonary Embolism in a Patient with Lung Adenocarcinoma.
    Liao JP; Nie LG; Que CL; Mu XD
    Chin Med J (Engl); 2017 Nov; 130(22):2755-2756. PubMed ID: 29133768
    [No Abstract]   [Full Text] [Related]  

  • 15. Novel drug targets based on association between inflammation and pancreatic ductal adenocarcinoma.
    Saif MW
    JOP; 2010 Jul; 11(4):403-4; author reply 411. PubMed ID: 20601821
    [No Abstract]   [Full Text] [Related]  

  • 16. Monoclonal antibody therapies targeting pancreatic ductal adenocarcinoma.
    Engelhardt K; Riley C; Cooke L; Mahadevan D
    Curr Drug Discov Technol; 2006 Dec; 3(4):231-43. PubMed ID: 17430101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis.
    Kudo F; Watanabe Y; Iwai Y; Miwa C; Nagai Y; Ota H; Yabe H; Demitsu T; Hagiwara K; Koyama N; Koyama S
    Intern Med; 2018 Aug; 57(15):2217-2221. PubMed ID: 29526968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial Remission of Hepatic Metastatic Lesion but Complicated with Secondary and Refractory Fever Lead by Nivolumab in a Patient with Lung Adenocarcinoma Presenting Gefitinib Acquired Resistance.
    Lian ZZ; Sun YF; Chen C
    Chin Med J (Engl); 2016 Apr; 129(7):879-80. PubMed ID: 26996489
    [No Abstract]   [Full Text] [Related]  

  • 19. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.
    Hiraoka N; Onozato K; Kosuge T; Hirohashi S
    Clin Cancer Res; 2006 Sep; 12(18):5423-34. PubMed ID: 17000676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report.
    Ikeuchi K; Okuma Y; Tabata T
    Lung Cancer; 2016 Sep; 99():148-50. PubMed ID: 27565931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.